Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

Fig. 2

Expression of genes defining molecular subtypes. Paired gene expression fold-changes of genes defining molecular subtypes at the time of progression compared to before initiation of bevacizumab therapy in responding patients. indicates the gene expression change according to the 25% percentile of subtype genes. * Modified Phillips classifier used on the AVAglio dataset

Back to article page